Olive oil compounds inhibit vascular endothelial growth factor receptor-2 phosphorylation

Experimental Cell Research

Volumn 322, Issue 1, 2014, Pages 89-98

  Lamy, Sylvie ^a   Ouanouki, Amira ^a   Béliveau, Richard ^a   Desrosiers, Richard R ^a  

^a UNIVERSITÉ DU QUÉBEC À MONTRÉAL   (Canada)

Author keywords

Angiogenesis; Endothelial cell; Olive oil; Signaling pathway; VEGF VEGFR 2

Indexed keywords

ANGIOGENESIS INHIBITOR; HYDROXYTYROSOL; OLEIC ACID; OLEUROPEIN; OLIVE OIL; RECOMBINANT VASCULOTROPIN; TAXIFOLIN; TYROSOL; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANALYZER; ANGIOGENESIS; ANTIOXIDANT ACTIVITY; ARTICLE; BIOSENSOR; CANCER PREVENTION; CELL MIGRATION ASSAY; CELL PROLIFERATION ASSAY; CELL VIABILITY; CHEMICAL STRUCTURE; CONTROLLED STUDY; ENDOTHELIUM CELL; FOOD; HUMAN; HUMAN CELL; MOLECULE; NUTRITION; OLIVE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING;

ANGIOGENESIS; ENDOTHELIAL CELL; OLIVE OIL; SIGNALING PATHWAY; VEGF/VEGFR-2;

CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; DOWN-REGULATION; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; NEOVASCULARIZATION, PHYSIOLOGIC; OLEIC ACID; PHENYLETHYL ALCOHOL; PHOSPHORYLATION; PLANT EXTRACTS; PLANT OILS; PROTEIN PROCESSING, POST-TRANSLATIONAL; QUERCETIN; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84893737264     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2013.11.022     Document Type: Article

References (54)

1. Folkman J. Angiogenesis. Annu. Rev. Med. 2006, 57:1-18.
2. Liekens S., De Clercq E., Neyts J. Angiogenesis: regulators and clinical applications. Biochem. Pharmacol. 2001, 61:253-270.
3. Folkman J., Shing Y. Angiogenesis. J. Biol. Chem. 1992, 267:10931-10934.
4. Ferrara N. VEGF-A: a critical regulator of blood vessel growth. Eur. Cytokine Netw. 2009, 20:158-163.
5. Cross M.J., Dixelius J., Matsumoto T., Claesson-Welsh L. VEGF-receptor signal transduction. Trends Biochem. Sci. 2003, 28:488-494.
6. Holmes K., Roberts O.L., Thomas A.M., Cross M.J. Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition. Cell Signal. 2007, 19:2003-2012.
7. Matsumoto T., Bohman S., Dixelius J., Berge T., Dimberg A., Magnusson P., Wang L., Wikner C., Qi J.H., Wernstedt C., Wu J., Bruheim S., Mugishima H., Mukhopadhyay D., Spurkland A., Claesson-Welsh L. VEGF receptor-2 Y951 signaling and a role for the adapter molecule TSAd in tumor angiogenesis. EMBO J. 2005, 24:2342-2353.
8. Dougher M., Terman B.I. Autophosphorylation of KDR in the kinase domain is required for maximal VEGF-stimulated kinase activity and receptor internalization. Oncogene 1999, 18:1619-1627.
9. Kendall R.L., Rutledge R.Z., Mao X., Tebben A.J., Hungate R.W., Thomas K.A. Vascular endothelial growth factor receptor KDR tyrosine kinase activity is increased by autophosphorylation of two activation loop tyrosine residues. J. Biol. Chem. 1999, 274:6453-6460.
10. Takahashi T., Yamaguchi S., Chida K., Shibuya M. A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-gamma and DNA synthesis in vascular endothelial cells. EMBO J. 2001, 20:2768-2778.
11. Underiner T.L., Ruggeri B., Gingrich D.E. Development of vascular endothelial growth factor receptor (VEGFR) kinase inhibitors as anti-angiogenic agents in cancer therapy. Curr. Med. Chem. 2004, 11:731-745.
12. Bhat T.A., Singh R.P. Tumor angiogenesis-a potential target in cancer chemoprevention. Food Chem. Toxicol.: Int. J. Publ. Br. Ind. Biol. Res. Assoc. 2008, 46:1334-1345.
13. Wiseman M. The second World Cancer Research Fund/American Institute for Cancer Research expert report. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. Proc. Nutr. Soc. 2008, 67:253-256.
14. Sofi F., Abbate R., Gensini G.F., Casini A. Accruing evidence on benefits of adherence to the Mediterranean diet on health: an updated systematic review and meta-analysis. Am. J. Clin. Nutr. 2010, 92:1189-1196.
15. Verberne L., Bach-Faig A., Buckland G., Serra-Majem L. Association between the Mediterranean diet and cancer risk: a review of observational studies. Nutr. Cancer 2010, 62:860-870.
16. Pelucchi C., Bosetti C., Negri E., Lipworth L., La Vecchia C. Olive oil and cancer risk: an update of epidemiological findings through 2010. Curr. Pharm. Des. 2011, 17:805-812.
17. Filik L., Ozyilkan O. Olive-oil consumption and cancer risk. Eur. J. Clin. Nutr. 2003, 57:191.
18. Cicerale S., Conlan X.A., Sinclair A.J., Keast R.S. Chemistry and health of olive oil phenolics. Crit. Rev. Food Sci. Nutr. 2009, 49:218-236.
19. Trichopoulou A., Lagiou P., Kuper H., Trichopoulos D. Cancer and Mediterranean dietary traditions. Cancer Epidemiol., Biomark. Prev.: Publ. Am. Assoc. Cancer Res. 2000, 9:869-873. ([cosponsored by the American Society of Preventive Oncology]).
20. Escrich E., Moral R., Grau L., Costa I., Solanas M. Molecular mechanisms of the effects of olive oil and other dietary lipids on cancer. Mol. Nutr. Food Res. 2007, 51:1279-1292.
21. Pauwels E.K. The protective effect of the Mediterranean diet: focus on cancer and cardiovascular risk. Med. Princ. Pract.: Int. J. Kuwait Univ., Health Sci. Cent. 2011, 20:103-111.
22. Rafehi H., Ververis K., Karagiannis T.C. Mechanisms of action of phenolic compounds in olive. J. Diet. Suppl. 2012, 9:96-109.
23. Owen R.W., Giacosa A., Hull W.E., Haubner R., Wurtele G., Spiegelhalder B., Bartsch H. Olive-oil consumption and health: the possible role of antioxidants. Lancet Oncol. 2000, 1:107-112.
24. Bendini A., Cerretani L., Carrasco-Pancorbo A., Gomez-Caravaca A.M., Segura-Carretero A., Fernandez-Gutierrez A., Lercker G. Phenolic molecules in virgin olive oils: a survey of their sensory properties, health effects, antioxidant activity and analytical methods. An overview of the last decade. Molecules 2007, 12:1679-1719.
25. Kontou N., Psaltopoulou T., Panagiotakos D., Dimopoulos M.A., Linos A. The mediterranean diet in cancer prevention: a review. J. Med. Food 2011, 14:1065-1078.
26. Charoenprasert S., Mitchell A. Factors influencing phenolic compounds in table olives (Olea europaea). J. Agric. Food Chem. 2012, 60:7081-7095.
27. Fabiani R., De Bartolomeo A., Rosignoli P., Servili M., Montedoro G.F., Morozzi G. Cancer chemoprevention by hydroxytyrosol isolated from virgin olive oil through G1 cell cycle arrest and apoptosis. Eur. J. Cancer Prev. 2002, 11:351-358.
28. Han J., Talorete T.P., Yamada P., Isoda H. Anti-proliferative and apoptotic effects of oleuropein and hydroxytyrosol on human breast cancer MCF-7 cells. Cytotechnology 2009, 59:45-53.
29. Scoditti E., Calabriso N., Massaro M., Pellegrino M., Storelli C., Martines G., De Caterina R., Carluccio M.A. Mediterranean diet polyphenols reduce inflammatory angiogenesis through MMP-9 and COX-2 inhibition in human vascular endothelial cells: a potentially protective mechanism in atherosclerotic vascular disease and cancer. Arch. Biochem. Biophys. 2012, 527:81-89.
30. Koch S., Tugues S., Li X., Gualandi L., Claesson-Welsh L. Signal transduction by vascular endothelial growth factor receptors. Biochem. J. 2011, 437:169-183.
31. Shen K., Ji L., Lu B., Wang Z. c-Jun N-terminal kinase mediated VEGFR2 sustained phosphorylation is critical for VEGFA-induced angiogenesis in vitro and in vivo. Cell Biochem. Biophys. 2012, 64:17-27.
32. Niu G., Chen X. Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy. Curr. Drug Targets 2010, 11:1000-1017.
33. Kamba T., McDonald D.M. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br. J. Cancer 2007, 96:1788-1795.
34. Lamy S., Gingras D., Beliveau R. Green tea catechins inhibit vascular endothelial growth factor receptor phosphorylation. Cancer Res. 2002, 62:381-385.
35. Lamy S., Blanchette M., MichaudLevesque J., Lafleur R., Durocher Y., Moghrabi A., Barrette S., Gingras D., Beliveau R. Delphinidin, a dietary anthocyanidin, inhibits vascular endothelial growth factor receptor-2 phosphorylation. Carcinogenesis 2006, 27:989-996.
36. Lamy S., Bedard V., Labbe D., Sartelet H., Barthomeuf C., Gingras D., Beliveau R. The dietary flavones apigenin and luteolin impair smooth muscle cell migration and VEGF expression through inhibition of PDGFR-beta phosphorylation. Cancer Prev. Res. (Phila Pa) 2008, 1:452-459.
37. Terzuoli E., Donnini S., Giachetti A., Iniguez M.A., Fresno M., Melillo G., Ziche M. Inhibition of hypoxia inducible factor-1alpha by dihydroxyphenylethanol, a product from olive oil, blocks microsomal prostaglandin-E synthase-1/vascular endothelial growth factor expression and reduces tumor angiogenesis. Clin. Cancer Res. 2010, 16:4207-4216.
38. Yuan L., Ahn I.S., Davis P.F. Inhibition of tyrosine phosphorylation of vascular endothelial growth factor receptors in human umbilical vein endothelial cells: a potent anti-angiogenic lipid-rich extract from shark. J. Med. Food 2007, 10:657-661.
39. Yuan L., Yoshida M., Davis P.F. Inhibition of pro-angiogenic factors by a lipid-rich shark extract. J. Med. Food 2006, 9:300-306.
40. Zeng H., Sanyal S., Mukhopadhyay D. Tyrosine residues 951 and 1059 of vascular endothelial growth factor receptor-2 (KDR) are essential for vascular permeability factor/vascular endothelial growth factor-induced endothelium migration and proliferation, respectively. J. Biol. Chem. 2001, 276:32714-32719.
41. Lamalice L., Houle F., Huot J. Phosphorylation of Tyr1214 within VEGFR-2 triggers the recruitment of Nck and activation of Fyn leading to SAPK2/p38 activation and endothelial cell migration in response to VEGF. J. Biol. Chem. 2006, 281:34009-34020.
42. Katz M., Amit I., Yarden Y. Regulation of MAPKs by growth factors and receptor tyrosine kinases. Biochim. Biophys. Acta 2007, 1773:1161-1176.
43. Uchida C., Gee E., Ispanovic E., Haas T.L. JNK as a positive regulator of angiogenic potential in endothelial cells. Cell Biol. Int. 2008, 32:769-776.
44. van Hinsbergh V.W., Koolwijk P. Endothelial sprouting and angiogenesis: matrix metalloproteinases in the lead. Cardiovasc. Res. 2008, 78:203-212.
45. Maragoudakis M.E., Missirlis E., Karakiulakis G.D., Sarmonica M., Bastakis M., Tsopanoglou N. Basement membrane biosynthesis as a target for developing inhibitors of angiogenesis with anti-tumor properties. Kidney Int. 1993, 43:147-150.
46. Miro-Casas E., Covas M.I., Farre M., Fito M., Ortuno J., Weinbrenner T., Roset P., de la Torre R. Hydroxytyrosol disposition in humans. Clin. Chem. 2003, 49:945-952.
47. Arab L. Biomarkers of fat and fatty acid intake. J. Nutr. 2003, 133(Suppl 3):925S-932S.
48. Visioli F., Galli C., Bornet F., Mattei A., Patelli R., Galli G., Caruso D. Olive oil phenolics are dose-dependently absorbed in humans. FEBS Lett. 2000, 468:159-160.
49. Vissers M.N., Zock P.L., Roodenburg A.J., Leenen R., Katan M.B. Olive oil phenols are absorbed in humans. J. Nutr. 2002, 132:409-417.
50. Serra A., Rubio L., Borras X., Macia A., Romero M.P., Motilva M.J. Distribution of olive oil phenolic compounds in rat tissues after administration of a phenolic extract from olive cake. Mol. Nutr. Food Res. 2012, 56:486-496.
51. Fito M., de la Torre R., Farre-Albaladejo M., Khymenetz O., Marrugat J., Covas M.I. Bioavailability and antioxidant effects of olive oil phenolic compounds in humans: a review. Ann. Ist. Super. Sanita 2007, 43:375-381.
52. Vissers M.N., Zock P.L., Katan M.B. Bioavailability and antioxidant effects of olive oil phenols in humans: a review. European J. Clin. Nutr. 2004, 58:955-965.
53. Covas M.I., de la Torre K., Farre-Albaladejo M., Kaikkonen J., Fito M., Lopez-Sabater C., Pujadas-Bastardes M.A., Joglar J., Weinbrenner T., Lamuela-Raventos R.M., de la Torre R. Postprandial LDL phenolic content and LDL oxidation are modulated by olive oil phenolic compounds in humans. Free Radic. Biol. Med. 2006, 40:608-616.
54. Zrelli H., Matsuka M., Araki M., Zarrouk M., Miyazaki H. Hydroxytyrosol induces vascular smooth muscle cells apoptosis through NO production and PP2A activation with subsequent inactivation of Akt. Planta Med. 2011, 77:1680-1686.